Anvisa Approves New Medicine for Advanced Lung Cancer - 20/10/2026 - Balance and Health
4 Articles
4 Articles
On Monday, Brazil became the second country in the world - after the US - to approve a new treatment for advanced lung cancer. It is telisotuzumab vedotine, a target therapy indicated for the treatment of adult patients with non-small cell lung cancer (CPNPC) non-squamous, locally advanced or metastatic, with high overexpression of c-Met1 protein, who received prior treatment. Approval represents a new advance in the treatment of lung cancer in …
Anvisa granted on Monday, 19, the registration of Emrelis (telisotuzumab vedotine), of the pharmaceutical AbbVie, for adults with advanced or metastatic lung cancer. The use is valid for patients whose tumor has a large amount of c-Met protein and who have already been treated before. Brazil is the second country to approve therapy,...
Anvisa (National Health Surveillance Agency) approved on Monday (19) the registration of Emrelis (telisotuzumab vedotine), a medicine indicated for adult patients with non-small cell lung cancer - the most common type of disease - advanced or metastatic. Read more (10/20/2026
Treatment is indicated for adults with non-small cell lung cancer; through Abbvie, Brazil is the second country to release the drug, after the USA
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
